Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]
Proposed [GID-TA10770] Expected publication date: TBC
Search results
169 results
-
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Proposed [GID-HST10039] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC
-
Avalglucosidase alfa for treating Pompe disease [ID3737]
Proposed [GID-HST10030] Expected publication date: TBC
-
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Proposed [GID-HST10037] Expected publication date: TBC
-
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Proposed [GID-TA10685] Expected publication date: TBC
-
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Proposed [GID-TA10662] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Proposed [GID-TA10700] Expected publication date: TBC
-
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]
Proposed [GID-TA10676] Expected publication date: TBC
-
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Proposed [GID-TA10763] Expected publication date: TBC
-
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
Proposed [GID-TA10666] Expected publication date: 26 August 2021
-
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]
Proposed [GID-TA10654] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
Proposed [GID-TA10714] Expected publication date: TBC
-
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Proposed [GID-TA10727] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Proposed [GID-TA10728] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Proposed [GID-TA10730] Expected publication date: TBC
-
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]
Proposed [GID-TA10739] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Proposed [GID-TA10536] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Proposed [GID-TA10758] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Proposed [GID-TA10741] Expected publication date: TBC
-
Antenatal care: draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 24 March 2021.
-
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Proposed [GID-TA10519] Expected publication date: TBC
-
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) ID3777
Proposed [GID-TA10810] Expected publication date: 22 October 2021
-
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]
Proposed [GID-TA10746] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Proposed [GID-TA10771] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Proposed [GID-TA10811] Expected publication date: TBC
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]
Proposed [GID-TA10812] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]
Proposed [GID-TA10813] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]
Proposed [GID-TA10814] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3933]
Proposed [GID-TA10815] Expected publication date: TBC
-
Mosunetuzumab for treating relapsed or refractory B-cell non-Hodgkin lymphoma [ID3931]
Proposed [GID-TA10816] Expected publication date: TBC
-
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]
Proposed [GID-TA10817] Expected publication date: TBC
-
Hypertension in adults: diagnosis and management (update): draft scope consultation
We are listening to your views on this NICE guideline. Comments close 16 March 2021.
-
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]
Proposed [GID-TA10719] Expected publication date: TBC
-
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
Proposed [GID-TA10706] Expected publication date: 20 October 2021
-
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]
Proposed [GID-TA10658] Expected publication date: 20 October 2021
-
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]
Proposed [GID-TA10732] Expected publication date: TBC
-
Sapropterin for treating phenylketonuria [ID1475]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 18 March 2021.
-
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Proposed [GID-TA10657] Expected publication date: TBC
-
Foslevodopa-foscarbidopa for treating Parkinson's disease with motor fluctuations [ID3876]
Proposed [GID-TA10772] Expected publication date: TBC
-
Gefapixant for treating refractory or unexplained chronic cough [ID3789]
Proposed [GID-TA10678] Expected publication date: TBC
-
Benralizumab for previously treated severe nasal polyps [ID1659]
Proposed [GID-TA10818] Expected publication date: TBC
-
Risankizumab for previously treated active psoriatic arthritis [ID1399]
Proposed [GID-TA10819] Expected publication date: TBC
-
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Proposed [GID-TA10535] Expected publication date: TBC